KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Implementation of genetic testing in breast cancer patients

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC

Breast cancer screening and treatment in Brazil

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer

Oral paclitaxel with encequidar in metastatic breast cancer

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients